Publications authored by CHSPR faculty and staff from 2009 to the present are listed here. Older peer-reviewed publications are usually available from individual journals and can be searched for using PubMed. Older reports published by CHSPR (from 1973) are available from the UBC Library cIRcle database. If you cannot find a specific publication, please contact us.
Law MR. Money left on the table: generic drug prices in Canada. Healthc Policy. 2013 Feb;8(3):17-25. Read more
Morgan SG, Thomson PA, Daw JR, Friesen MK, Dijkstra A. The public provision of pharmaceuticals: a synthesis of policies in ten developed countries. Vancouver (BC): Pharmaceutical Policy Research Collaboration; Dec 2012. Read more
Morgan SG, Daw JR. Canadian pharmacare: looking back, looking forward. Healthc Policy. 2012 Aug;8(1):14-23. Read more
Evans RG. A Casualty in the Class War: Canada's Medicare. Healthc Policy. 2012 Feb;7(3):14-22. Read more
Daw JR, Morgan SG. Stitching the gaps in the Canadian public drug coverage patchwork?: a review of provincial pharmacare policy changes from 2000 to 2010. Health Policy. 2012 Jan;104(1):19-26. Read more
Evans RG. Hancocked: Manulife and the limits of private health insurance. Healthc Policy. 2011 Aug;7(1):14-21. Read more
Law MR, Ystma A, Morgan SG. The short-term impact of Ontario's generic pricing reforms. PLoS One. 2011;6(7):e23030. Read more
Hanley GE, Morgan S, Barer M, Reid RJ. The redistributive effect of the move from age-based to income-based prescription drug coverage in British Columbia, Canada. Health Policy. 2011 Jul;101(2):185-94. Read more
Chafe R, Culyer A, Dobrow M, Coyte PC, Sawka C, O'Reilly S, Laing K, Trudeau M, Smith S, Hoch JS, Morgan S, Peacock S, Abbott R, Sullivan T. Access to cancer drugs in Canada: looking beyond coverage decisions. Healthc Policy. 2011 Feb;6(3):27-36. Read more
Lu CY, Law MR, Soumerai SB, Graves AJ, LeCates RF, Zhang F, Ross-Degnan D, Adams AS. Impact of prior authorization on the use and costs of lipid-lowering medications among Michigan and Indiana dual enrollees in Medicaid and Medicare: results of a longitudinal, population-based study. Clin Ther. 2011 Jan;33(1):135-44. Read more
Morgan S, Boothe K. Prescription drug subsidies in Australia and New Zealand. Aust Prescriber 2010;33(1):2-4. Read more
Evans RG. Universal Health care insurance in Canada: achievements, limits, stresses, threats, and scope for improvement. In: Universidad Nacional Autonoma de Mexico, editor. 1er Congreso Internacional Hacia una Cobertura Universal en Salud; April 22-24, 2009; Mexico: Organizacion panamericana de la salud; 2009. 51-79. Read more
Morgan S, Hanley G, Greyson D. Comparison of tiered formularies and reference pricing policies: a systematic review. Open Med. 2009;3(3):e131-9. Read more
Law MR, Soumerai SB, Adams AS, Majumdar SR. Costs and consequences of direct-to-consumer advertising for clopidogrel in Medicaid. Arch Intern Med. 2009 Nov 23;169(21):1969-74. Read more
Morgan S, Hanley G, Raymond C, Blais R. Breadth, Depth and Agreement among Provincial Formularies in Canada. Healthc Policy. 2009 May;4(4):e162-84. Read more
Evans RG. Old bones, new data: Emmett Hall, private insurance and the defeat of pharmacare. Healthc Policy. 2009 Feb;4(3):16-24. Read more
Morgan S. Challenges and changes in pharmacare: could social insurance be the answer? In: Flood CM, Stabile M, Touhy C, editors. Exploring social insurance: can a dose of Europe cure Canadian health care finance? Montreal and Kingston: School of Policy Studies at Queen's U and McGill U; 2008. 199-220. Read more
Evans RG. Separate and unequal: self-segregation in health insurance. Med Care. 2008 Oct;46(10):1012-4. Read more
Morgan SG, Cunningham C. The effect of evidence-based drug coverage policies on pharmaceutical r&d: a case study from British Columbia. Healthc Policy. 2008 Feb;3(3):e128-53. Read more
Morgan S, Hanley G, McMahon M, Barer M. Influencing drug prices through formulary-based policies: lessons from New Zealand. Healthc Policy. 2007 Aug;3(1):e121-40. Read more